Major Antiretroviral Toxicities Described in the WHO Consolidated Guidelines on the Use of Antiretroviral Drugs for Treating and Prevention HIV Infection 201638
| Antiretroviral Drug | Toxicity |
|---|---|
| Abacavir | Hypersensitivity reaction |
| Atazanavir/r | Electrocardiographic abnormalities (PR and QRS interval prolongation) Indirect hyperbilirubinemia (clinical jaundice) Nephrolithiasis |
| Zidovudine | Severe anemia, neutropenia Lactic acidosis or severe hepatomegaly with steatosis Lipoatrophy Lipodystrophy Myopathy |
| Darunavir/r | Hepatotoxicity Severe skin and hypersensitivity reactions |
| Dolutegravir | Hepatotoxicity Hypersensitivity reactions |
| Efavirenz | Persistent central nervous system toxicity (such as dizziness, insomnia, abnormal dreams) or mental symptoms (anxiety, depression, mental confusion) Convulsions Hepatotoxicity Severe skin and hypersensitivity reactions Gynecomastia Severe skin and hypersensitivity reactions |
| Lopinavir/r | Electrocardiographic abnormalities (PR and QRS interval prolongation, torsades de pointes) Hepatotoxicity Pancreatitis Dyslipidemia Diarrhea |
| Nevirapine | Hepatotoxicity Severe skin rash and hypersensitivity reaction, including Stevens-Johnson syndrome |
| Raltegravir | Rhabdomyolysis, myopathy, myalgia Hepatitis and hepatic failure Severe skin rash and hypersensitivity reaction |
| Tenofovir Disoproxil Fumarate | Chronic kidney disease Acute kidney injury and Fanconi syndrome Decreases in bone mineral density Lactic acidosis or severe hepatomegaly with steatosis |